COHBAR, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7601 USD | -23.98% |
|
0.00% | +2.72% |
| Jan. 23 | North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up | DJ |
| Jan. 16 | North American Morning Briefing : Stock Futures -2- | DJ |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is Latonya, and I will...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.72% | 2.91M | |
| +39.37% | 54.04B | |
| +44.87% | 41.96B | |
| -1.40% | 41.92B | |
| -7.20% | 28.35B | |
| +12.47% | 26.35B | |
| -21.76% | 19B | |
| +6.98% | 13B | |
| +29.20% | 12.28B | |
| +26.32% | 12.19B |
- Stock Market
- Equities
- CWBR Stock
- News CohBar, Inc.
- Transcript : CohBar, Inc., Q3 2019 Earnings Call, Nov 06, 2019